Recombinant HCV genotype 2b Core Antigen [His]

Name: Recombinant HCV genotype 2b Core Antigen [His]
SKU: DAG-P2941
Rating: 5 (1 reviews)

HCV genotype 2b Core Antigen, recombinant protein from E. coli

COA

SDS

Datasheet

Summary

Nature

Recombinant

Tag/Conjugate

His

Purity

≥85% as determined by SDS-PAGE

Format

Liquid or Lyophilized powder

Buffer

Tris/PBS-based buffer, 5%-50% glycerol

Preservative

None

Storage

Store at -20°C to -80°C

Introduction

Hepatitis C Virus is a positive, single stranded RNA virus in the Flaviviridae family. The genome is approximately 10,000 nucleotides and encodes a single polyprotein of about 3,000 amino acids. The polyprotein is processed by host cell and viral protease

Keywords

HCV 2b; HCV Core 2b; HCV Core Genotype 2b; HCV2b; Hepatitis C Virus Core genotype 2b; HCV Core 2b

Citations

Have you cited DAG-P2941 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Hepatitis B virus, hepatitis C virus and human immunodeficiency virus infection in undocumented migrants and refugees in southern Italy, January 2012 to June 2013

EUROSURVEILLANCE

Authors: Coppola, N.; Alessio, L.; Gualdieri, L.; Pisaturo, M.; Sagnelli, C.; Caprio, N.; Maffei, R.; Starace, M.; Angelillo, I. F.; Pasquale, G.; Sagnelli, E.

Abstract

Screening of undocumented migrants or refugees for hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infections has been offered free of charge and free from bureaucratic procedures since 2012 at four primary-level clinical centres in Naples and Caserta, Italy. Of 926 undocumented migrants and refugees visiting one of the primary-level clinical centres from January 2012 to June 2013, 882 (95%) were screened for hepatitis B surface antigen (HBsAg), total hepatitis B core antibody (anti-HBc) and antibodies against HCV and HIV. Of the 882 individuals enrolled, 78 (9%) were HBsAg positive, 35 (4%) anti-HCV positive and 11 (1%) anti-HIV positive (single infections); seven (1%) had more than one infection (three were HBsAg positive). Of the 801 HBsAg-negative patients, 373 (47%) were anti-HBc positive. The HBsAg-positivity rate was high (14%; 62/444) in individuals from sub-Saharan Africa and intermediate in those from eastern Europe (6%; 12/198), northern Africa (2%; 2/80) and Bangladesh, India, Pakistan and Sri Lanka (the 'India-Pakistan area') (3%; 4/126). Anti-HCV was detected in 9/126 (7%) individuals originating from the India-Pakistan area, in 12/198 (6%) from eastern Europe, in 17/444 (4%) from sub-Saharan and in 2/80 (2%) from northern Africa. The HBV, HCV and HIV infections in the undocumented migrants and refugees screened serve as a reminder to the Italian healthcare authorities to carry out extensive screening and educational programmes for these populations.

Developments in the HCV Screening Technologies Based on the Detection of Antigens and Antibodies

SENSORS

Authors: Warkad, Shrikant Dashrath; Song, Keum-Soo; Pal, Dilipkumar; Nimse, Satish Balasaheb

Abstract

Hepatitis C virus (HCV) accounts for 15%-20% of cases of acute infection, and chronic HCV infection is developed in about 50%-80% of HCV patients. Unfortunately, due to the lack of proper medical care, difficulty in screening for HCV infection, and lack of awareness resulted in chronic HCV infection in 71 million people on a global scale, and about 399,000 deaths in 2016. It is crucial to recognize that the effective use of antiviral medicines can cure more than 95% of HCV infected people. The Global Health Sector Strategy (GHSS) aim is to reduce the new HCV infections and the HCV associated mortality by 90% and 65%, respectively. Therefore, the methods that are simple, yet powerful enough to detect HCV infections with high sensitivity, specificity, and a shorter window period are crucial to restrain the global burden of HCV healthcare. This article focuses on the technologies used for the detection of HCV in clinical specimens.